Alectinib FDA approved for ALK-positive metastatic NSCLC

Non-Sponsored Content

By: scienterrific | Last updated: 6 November 2017 | In: US FDA Onc\Haem Approvals, Uncategorised

Article Keywords

Genentech, Alecensa, alectinib, ALK, Roche, FDA

On 6 November 2017, the FDA granted regular approval to alectinib (Alecensa®, Roche/Genentech) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

Non-Sponsored Content